Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
Date:2/11/2009

with the workforce reduction. The decrease in stock-based compensation in the fourth quarter of 2008 relative to the fourth quarter of 2007 is primarily due to the lower fair market value of options granted in 2008 and the reversal of cumulative amortization of deferred stock-based compensation related to the cancellation of unvested options in connection with the workforce reduction. For the full year of 2008, total stock-based compensation was $13.4 million, compared to $19.5 million for the prior year.

  • Net loss for the fourth quarter of 2008 was $7.5 million, compared to a net loss of $10.9 million for the third quarter of 2008 and $20.7 million for the fourth quarter of 2007. For the full year of 2008, net loss was $51.1 million, compared to $74.1 million for the full year of 2007.

  • Net loss per common share for the fourth quarter of 2008 was $0.28, compared to $0.41 for the third quarter of 2008 and $0.78 for the fourth quarter of 2007. For the full year of 2008, net loss per common share was $1.92, compared to $2.81 for the full year of 2007.

  • Cash and marketable securities decreased by $5.2 million during the fourth quarter of 2008. Changes included $7.5 million of net losses, decreases in accrued R&D expenses and accounts payable of $0.6 million, offset by decreases in prepaid expenses of $1.7 million, $0.8 million in non-cash depreciation, amortization, and stock-based compensation expenses and net decreases in other working capital of $0.4 million.

  • Vanda's cash, cash equivalents and marketable securities as of December 31, 2008 totaled approximately $46.5 million, compared to approximately $51.7 million as of September 30, 2008 and $93.2 million as of December 31, 2007.

FINANCIAL GUIDANC
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
2. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
3. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
4. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
5. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
6. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
8. Sagent Pharmaceuticals Announces Expansion of Cefazolin Product Line to Include Cefazolin for Injection, USP in 500mg Single-Dose Vial
9. PacificGMP and LigoCyte Pharmaceuticals Announce cGMP Manufacturing Collaboration
10. Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida
11. Tigris Pharmaceuticals Files IND Application for GGTI-2418
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 23, 2014 According to Ross ... Island Affiliate of ITRA Global, the national office market continues ... recovery. This is evidenced by the third quarter’s surprising ... market. Low energy costs have held inflation down and ... negative is the housing market remaining soft. , This solid ...
(Date:12/24/2014)... Pipette.com announces their Holiday in the ... their #HolidayInTheLab pictures for a chance to win pipette-themed ... those struggling to think of a holiday gift for ... Lab Contest provides the ideal holiday presents. The #HolidayInTheLab ... pictures of their chemistree, holiday sweaters, as well as ...
(Date:12/24/2014)... Dec. 23, 2014 Sigma-Aldrich Corporation (NASDAQ: ... waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... on December 22, 2014, thereby completing the U.S. ... the acquisition of the Company by Merck KGaA, ... satisfies another condition to closing the transaction, which ...
(Date:12/22/2014)... Dec. 22, 2014   Synthetic Biologics, ... of pathogen-specific therapies for serious infections and ... microbiome, today announced positive topline safety and ... trial of SYN-004, the Company,s investigational oral ... Clostridium difficile (C. difficile) infection, antibiotic-associated ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3Major Pipette Distributor Pipette.com Announces their Holiday in the Lab Contest 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5
... MILWAUKEE Merge eFilm , a Wisconsin-based ... announced the release of FUSION PACS version 1.2.7. ... additional image manipulation tools, image viewer plug-in and ... drive toward an electronic medical record makes provision ...
... transformation. Such a dramatic change has not ... brewing, automotive and agriculture industries were beginning to ... agriculture and manufacturing-based state economy to a knowledge ... finds itself competing in a global marketplace and ...
... sat down with Tom Still, the president of the ... tenets of the organization and initiatives Still and others ... Read Part One. , , Wisconsin ... Technology Council has encountered and what are your greatest ...
Cached Biology Technology:Educate, innovate and execute: Wisconsins model for success 2Educate, innovate and execute: Wisconsins model for success 3WTN exclusive interview with Tom Still, Wisconsin Technology Council - Part 2 2WTN exclusive interview with Tom Still, Wisconsin Technology Council - Part 2 3WTN exclusive interview with Tom Still, Wisconsin Technology Council - Part 2 4
(Date:12/10/2014)... 08, 2014 Research and Markets ... the "Biometrics Market in Japan 2014-2018" ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of ... rural banking and upgradation of the driver,s license ... the market. Besides the aforementioned projects, biometrics is ...
(Date:12/3/2014)... , Dec. 2, 2014   Marvin Test ... innovative test solutions for military, aerospace, and manufacturing ... of its successful TS-900 PXI semiconductor test ... features of high-end systems to customers at a ... compared to traditional ATE. "Our ...
(Date:11/21/2014)... , Nov. 20, 2014 C-Labs LLC, ... the Internet of Things (IoT), today announced the appointment ... chief operating officer. Previously a strategic advisor to the ... and operations. Mr. Traynor is based out of the ... He reports to Chris Muench , Chief Executive ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... announced the end of the Human Genome Project, the ... thymine, cytosine, and guanineis unique to homo sapien DNA. ... genes coded in the human genome, but as time ... genes are controlled. Now, Harvard Stem Cell Institute ...
... Societies for Experimental Biology (FASEB) is proud to announce the ... were unveiled on FASEB,s web site and will be ... main campus. "The competition provides a glimpse into the exciting ... Margaret K. Offermann, MD, PhD. "The winning images and videos ...
... at The University of Texas at San Antonio (UTSA) ... investing $200,000 in new research to develop a low-cost ... the next year, the researchers will optimize an inexpensive ... It will be tested on water samples from the ...
Cached Biology News:HSCI researchers extend human epigenomic map 2FASEB announces BioArt image and video competition winners 2UTSA, Southwest Research Institute to develop low-cost method to treat fracking water 2